According to the literature, TBK1 inhibitors alleviate the pathological response of NAFLD, suggesting that TBK1 is associated with NAFLD (Oral et al., 2017; Huh et al., 2020). Here, TBK1 is linked to metabolic dysfunction-associated steatotic liver disease.